Data gathered: July 26
Alternative Data for NovoCure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 37 | Sign up | Sign up | Sign up |
| Sentiment | 63 | Sign up | Sign up | Sign up |
| Webpage traffic | 29,000 | Sign up | Sign up | Sign up |
| Employee Rating | 63 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 195 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,292 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,694 | Sign up | Sign up | Sign up |
| Twitter Mentions | 51 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 46 | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,363 | Sign up | Sign up | Sign up |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
| Price | $19.02 |
| Target Price | Sign up |
| Volume | 1,170,000 |
| Market Cap | $2.02B |
| Year Range | $11.83 - $24.05 |
| Dividend Yield | 0% |
| Industry | Medical & Dental Instruments |
In the news
 |
NovoCure stock gains on robust Optune expansion in France says H.C. WainwrightJuly 26 - Investing.com |
 |
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q2 2024July 25 - Biztoc.com |
 |
NovoCure Limited (NVCR) Q2 2024 Earnings Call TranscriptJuly 24 - SeekingAlpha |
 |
NovoCure: Q2 Earnings SnapshotJuly 24 - Yahoo |
|
NovoCure Limited 2024 Q2 - Results - Earnings Call PresentationJuly 24 - SeekingAlpha |
NovoCure Ltd (NVCR) Q2 2024 Earnings: Revenue Surpasses Estimates at $150.4M, EPS Misses at -$0.31July 24 - GuruFocus |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 150M | 35M | 116M | -33M | -27M | -0.310 |
| Q1 '24 | 139M | 34M | 105M | -39M | -34M | -0.360 |
| Q4 '23 | 134M | 33M | 101M | -47M | -15M | -0.450 |
| Q3 '23 | 127M | 32M | 95M | -49M | -52M | -0.460 |
| Q2 '23 | 126M | 34M | 92M | -57M | -56M | -0.540 |
Insider Transactions View All
| LEUNG GABRIEL filed to sell 78,175 shares at $23.9. June 6 '24 |
| Scannell Timothy J filed to sell 2,964 shares at $23.9. June 6 '24 |
| VERNON W ANTHONY filed to sell 164,833 shares at $23.9. June 6 '24 |
| Leonard Frank X filed to sell 160,098 shares at $16. March 5 '24 |
| GROENHUYSEN WILHELMUS CM filed to sell 251,235 shares at $16. March 5 '24 |
Similar companies
Read more about NovoCure (NVCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of NovoCure?
The Market Cap of NovoCure is $2.02B.
What is the current stock price of NovoCure?
Currently, the price of one share of NovoCure stock is $19.02.
How can I analyze the NVCR stock price chart for investment decisions?
The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.
Does NVCR offer dividends to its shareholders?
As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NovoCure?
Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Silk Road Medical.
.